(mo)BETTA Trial in Transwomen for Optimization of ART
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of a new HIV
medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV
medications combined into one pill) in HIV-infected transgender women (TW).
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston